Skip Intro

Dracen Pharmaceuticals, Inc.

In March 2018, Deerfield invested $36 million in Dracen Pharmaceuticals, Inc as part of a $40 million Series A. Dracen is a private company developing proprietary anti-cancer drugs discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences.